Open Access

Cutaneous adverse reactions in a lung cancer patient treated with pembrolizumab: A case report

  • Authors:
    • Carmen Bobeica
    • Laura Rebegea
    • Gabriel Murariu
    • Michaela Dobre
    • Aurel Nechita
    • Alin Laurentiu Tatu
    • Elena Niculet
    • Lucretia Anghel
    • Silvia Fotea
    • Mihaela Craescu
  • View Affiliations

  • Published online on: October 29, 2021     https://doi.org/10.3892/etm.2021.10937
  • Article Number: 15
  • Copyright: © Bobeica et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Lung cancer is the main cause of oncological death in the US and worldwide, constituting a significant public health problem. The incidence of lung cancer is on the increase. In the present study, the diagnostic process was carried out and treatment options were considered to determine the therapeutic response of a patient diagnosed with lung cancer. The case of an early stage lung cancer patient who benefited from surgical treatment was presented. The pathology report stated the complete diagnosis to be pleomorphic lung cancer with an adenocarcinoma component, pT2aN0M0, with focal positivity for thyroid transcription factor 1 (TTF1), without epidermal growth factor receptor (EGFR) mutations and ALK recombinations, having an initial clinical stage of IB and programmed death ligand‑1 (PD‑L1) positivity with a tumor proportion score of over 70%. The patient underwent radiotherapy treatment and was administered osteoclast inhibitors and immunotherapy, with no favorable therapeutic effect and with the presence of secondary cutaneous adverse effects to pembrolizumab. As a main cause of death, lung cancer registers a low general survival rate even in patients with targeted therapies or immunotherapy. By better identifying the patients at risk, one can establish a more efficient personalized treatment; the future objective of scientific studies is the follow‑up of adverse effects of new therapies.
View Figures
View References

Related Articles

Journal Cover

January-2022
Volume 23 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Bobeica C, Rebegea L, Murariu G, Dobre M, Nechita A, Tatu AL, Niculet E, Anghel L, Fotea S, Craescu M, Craescu M, et al: Cutaneous adverse reactions in a lung cancer patient treated with pembrolizumab: A case report. Exp Ther Med 23: 15, 2022
APA
Bobeica, C., Rebegea, L., Murariu, G., Dobre, M., Nechita, A., Tatu, A.L. ... Craescu, M. (2022). Cutaneous adverse reactions in a lung cancer patient treated with pembrolizumab: A case report. Experimental and Therapeutic Medicine, 23, 15. https://doi.org/10.3892/etm.2021.10937
MLA
Bobeica, C., Rebegea, L., Murariu, G., Dobre, M., Nechita, A., Tatu, A. L., Niculet, E., Anghel, L., Fotea, S., Craescu, M."Cutaneous adverse reactions in a lung cancer patient treated with pembrolizumab: A case report". Experimental and Therapeutic Medicine 23.1 (2022): 15.
Chicago
Bobeica, C., Rebegea, L., Murariu, G., Dobre, M., Nechita, A., Tatu, A. L., Niculet, E., Anghel, L., Fotea, S., Craescu, M."Cutaneous adverse reactions in a lung cancer patient treated with pembrolizumab: A case report". Experimental and Therapeutic Medicine 23, no. 1 (2022): 15. https://doi.org/10.3892/etm.2021.10937